Global Non-Infectious Macular Edema Treatment Strategic Business Report 2022: 46 Companies Featured Including AbbVie, Alimera Sciences, Allergan and Amgen - ResearchAndMarkets.com

The "Non-Infectious Macular Edema Treatment: Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.

The global market for Non-Infectious Macular Edema Treatment estimated at US$12.7 Billion in the year 2020, is projected to reach a revised size of US$18.6 Billion by 2027, growing at a CAGR of 5.6% over the analysis period 2020-2027.

Anti-VEGF, one of the segments analyzed in the report, is projected to record a 5.3% CAGR and reach US$12.5 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Corticosteroids segment is readjusted to a revised 6.8% CAGR for the next 7-year period.

The U.S. Market is Estimated at $3.8 Billion, While China is Forecast to Grow at 5.2% CAGR

The Non-Infectious Macular Edema Treatment market in the U.S. is estimated at US$3.8 Billion in the year 2020. China, the world's second largest economy, is forecast to reach a projected market size of US$3.3 Billion by the year 2027 trailing a CAGR of 5.2% over the analysis period 2020 to 2027.

Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.2% and 4.5% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.6% CAGR.

Immunosuppressants Segment to Record 6.2% CAGR

In the global Immunosuppressants segment, USA, Canada, Japan, China and Europe will drive the 6.2% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$979.8 Million in the year 2020 will reach a projected size of US$1.5 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets.

Select Competitors (Total 46 Featured) -

• AbbVie, Inc.
• Alimera Sciences, Inc.
• Allergan PLC
• Amgen, Inc.
• Bausch Health Companies, Inc.
• Bayer AG
• Clearside Biomedical, Inc.
• F. Hoffmann-La Roche AG
• Novartis International AG
• Pfizer, Inc.

What's New for 2022?

• Global competitiveness and key competitor percentage market shares
• Market presence across multiple geographies - Strong/Active/Niche/Trivial
• Online interactive peer-to-peer collaborative bespoke updates
• Access to digital archives and Research Platform
• Complimentary updates for one year

Key Topics Covered:

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

• Influencer Market Insights
• World Market Trajectories
• Non-infectious Macular Edema Treatment - Global Key Competitors Percentage Market Share in 2022 (E)
• Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
• Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

III. MARKET ANALYSIS

IV. COMPETITION

For more information about this report visit https://www.researchandmarkets.com/r/vysqxr

View source version on businesswire.com: https://www.businesswire.com/news/home/20221212005532/en/